Bavarian Nordic Receives USD 1.57 Billion from the US for Smallpox/Mpox Vaccine

Agreement Replenishes Vaccine Inventory and Secures Future Manufacturing Capacity

### Key Takeaways

• Bavarian Nordic has secured a USD 1.57 billion contract from the US Department of Health and Human Services (HHS).
• The contract covers the supply of smallpox/mpox vaccine and associated services over the next decade.
• The deal will replenish the US's strategic stockpile of the vaccine and ensure future manufacturing capacity.

Bavarian Nordic, a Danish biotechnology company, has announced a major agreement with the US government to supply smallpox/mpox vaccine over the next decade. The contract, valued at USD 1.57 billion, will support the replenishment of the US's strategic vaccine stockpile and secure future manufacturing capacity.

The contract follows the successful use of Bavarian Nordic's smallpox vaccine in combating the recent outbreak of mpox in 2022. The agreement will ensure that the US has access to a sufficient supply of the vaccine to respond to any future outbreaks of smallpox or mpox.

"We are pleased to have been selected by the US government to supply our smallpox/mpox vaccine," said Paul Chaplin, President and CEO of Bavarian Nordic. "This contract is a testament to the quality and effectiveness of our vaccine and underscores the importance of being prepared for potential threats to public health."

The US government's decision to invest in smallpox/mpox vaccine reflects the growing recognition of the potential threat posed by these diseases. Smallpox is a highly contagious and potentially fatal disease, while mpox is a related virus that can also cause serious illness.

Bavarian Nordic's commitment to developing and supplying vaccines for emerging infectious diseases underscores the company's mission of protecting global public health.